These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 5012168

  • 21. Carbamyl phosphate mediated inhibition of the sickling of erythrocytes in vitro.
    Kraus LM, Kraus AP.
    Biochem Biophys Res Commun; 1971 Sep 17; 44(6):1381-7. PubMed ID: 4946263
    [No Abstract] [Full Text] [Related]

  • 22. Effect of cyanate on sickling.
    May A, Bellingham AJ, Huehns ER, Beaven GH.
    Lancet; 1972 Mar 25; 1(7752):658-61. PubMed ID: 4125163
    [No Abstract] [Full Text] [Related]

  • 23. Biphasic blood oxygen dissociation curves in hemoglobin S hemoglobinopathies. Sickle cell heterozygotes.
    Cameron BF.
    Biochem Biophys Res Commun; 1971 May 21; 43(4):888-92. PubMed ID: 5105606
    [No Abstract] [Full Text] [Related]

  • 24. Biochemical and physiological properties of carbamylated hemoglobin S.
    Manning JM, Cerami A, Gillette PN, De Furia FG, Miller DR.
    Adv Enzymol Relat Areas Mol Biol; 1974 May 21; 40(0):1-27. PubMed ID: 4600763
    [No Abstract] [Full Text] [Related]

  • 25. Carbamyl phosphate modification of hemoglobin S structure resulting in altered sickling.
    Kraus LM, Rasad A, Kraus AP.
    Adv Exp Med Biol; 1972 May 21; 28():279-96. PubMed ID: 5085172
    [No Abstract] [Full Text] [Related]

  • 26. Enhancement of filterability of sickle cells by cyanate: an effect independent of oxygen saturation.
    Wagner SM, Bishop J, Flanigan PW, Bromberg PA, Balcerzak SP.
    J Lab Clin Med; 1975 Mar 21; 85(3):445-50. PubMed ID: 1117207
    [Abstract] [Full Text] [Related]

  • 27. Nitrogen mustard: an "in vitro" inhibitor of erythrocyte sickling.
    Roth EF, Nagel RL, Bookchin RM, Grayzel AI.
    Biochem Biophys Res Commun; 1972 Aug 07; 48(3):612-8. PubMed ID: 5047691
    [No Abstract] [Full Text] [Related]

  • 28. Studies on the mechanism of action of cyanate in sickle cell disease. Oxygen affinity and gelling properties of hemoglobin S carbamylated on specific chains.
    Nigen AM, Njikam N, Lee CK, Manning JM.
    J Biol Chem; 1974 Oct 25; 249(20):6611-6. PubMed ID: 4421180
    [No Abstract] [Full Text] [Related]

  • 29. Urea, urease, cyanate, and the sickling of hemoglobin S.
    Nalbandian RM, Nichols BM, Stehouwer EJ, Camp FR.
    Clin Chem; 1972 Sep 25; 18(9):961-4. PubMed ID: 5052097
    [No Abstract] [Full Text] [Related]

  • 30. Review of the development of cyanate as a drug in the treatment of sickle cell anemia.
    Cerami A.
    Ann N Y Acad Sci; 1974 Nov 29; 241(0):538-44. PubMed ID: 4611307
    [No Abstract] [Full Text] [Related]

  • 31. Pyridoxine administration in sickle cell disease: an unsuccessful attempt to influence the properties of sickle hemoglobin.
    Beutler E, Paniker NV, West CJ.
    Biochem Med; 1972 Apr 29; 6(2):139-43. PubMed ID: 5027148
    [No Abstract] [Full Text] [Related]

  • 32. Increased survival of sickle-cell erythrocytes after treatment in vitro with sodium cyanate.
    Gillette PN, Manning JM, Cerami A.
    Proc Natl Acad Sci U S A; 1971 Nov 29; 68(11):2791-3. PubMed ID: 5288258
    [Abstract] [Full Text] [Related]

  • 33. An extracorporeal system that modifies hemoglobin in patients with sickle cell anemia.
    Babb AL, Scribner BH, Uvelli DA, Fry DL, Agodoa LC.
    Artif Organs; 1979 Feb 29; 3(1):62-72. PubMed ID: 435126
    [No Abstract] [Full Text] [Related]

  • 34. Substituted benzaldehydes designed to increase the oxygen affinity of human haemoglobin and inhibit the sickling of sickle erythrocytes.
    Beddell CR, Goodford PJ, Kneen G, White RD, Wilkinson S, Wootton R.
    Br J Pharmacol; 1984 Jun 29; 82(2):397-407. PubMed ID: 6733364
    [Abstract] [Full Text] [Related]

  • 35. Sickle-cell anemia: molecular and cellular bases of therapeutic approaches (second of three parts).
    Dean J, Schechter AN.
    N Engl J Med; 1978 Oct 12; 299(15):804-11. PubMed ID: 692564
    [No Abstract] [Full Text] [Related]

  • 36. Hematologic and clinical responses in patients with sickle cell anemia after chronic extracorporeal red cell carbamylation.
    Deiderich DA, Trueworthy RC, Gill P, Cader AM, Larsen WE.
    J Clin Invest; 1976 Sep 12; 58(3):642-53. PubMed ID: 956392
    [Abstract] [Full Text] [Related]

  • 37. Urea, cyanate and sickling.
    Harris A.
    N Engl J Med; 1971 Sep 16; 285(12):690-1. PubMed ID: 5563487
    [No Abstract] [Full Text] [Related]

  • 38. Decreased life span and membrane damage of carbamylated erythrocytes in vitro.
    Lane TA, Burka ER.
    Blood; 1976 Jun 16; 47(6):909-17. PubMed ID: 1276471
    [Abstract] [Full Text] [Related]

  • 39. The effects of phenothiazines on the sickling phenomenon in vitro.
    McFadzean JA, Pugh IM, Squires SL.
    Br J Haematol; 1969 Jun 16; 16(1):173-80. PubMed ID: 4893926
    [No Abstract] [Full Text] [Related]

  • 40. Pyridoxal phosphate as an antisickling agent in vitro.
    Kark JA, Tarassoff PG, Bongiovanni R.
    J Clin Invest; 1983 May 16; 71(5):1224-9. PubMed ID: 6853710
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.